BAM
CYTK icon

Blueshift Asset Management’s Cytokinetics CYTK Stock Holding History

Blueshift Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,679
Closed -$234K – 526
2025
Q4 		$234K Buy
+3,679
New +$229K 0.07% 384
2022
Q1 		– Sell
-8,396
Closed -$383K – 889
2021
Q4 		$383K Sell
8,396
-4,905
-37% -$189K 0.03% 556
2021
Q3 		$475K Buy
+13,301
New +$392K 0.03% 648
2021
Q2 		– Sell
-9,089
Closed -$211K – 962
2021
Q1 		$211K Buy
+9,089
New +$194K 0.02% 758

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Blueshift Asset Management's CYTK Position: Q1 2026 in Review

Blueshift Asset Management sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 3,679 shares — an estimated $234K sold.

Blueshift Asset Management first reported a position in CYTK in Q1 2021 and held it in 4 quarters. The position peaked at $475K in Q3 2021. 441 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Blueshift Asset Management reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Blueshift Asset Management sold 3,679 Cytokinetics shares in Q1 2026, an estimated $234K.
  • Blueshift Asset Management first reported a position in Cytokinetics in Q1 2021 and held it in 4 quarters.
  • Blueshift Asset Management's Cytokinetics position peaked at $475K in Q3 2021.
  • 441 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Blueshift Asset Management's 13F filing for Q1 2026, filed 14 May 2026.